Literature DB >> 35620214

Treatment efficacy and prognosis analysis in locally advanced or metastatic colorectal cancer patients with hydronephrosis.

Gangling Tong1, Boran Chen1, Mingying Zhang1,2, Tianyu Wang3, Xuan Wu1, Yuye Yan1, Shubin Wang1, Shuluan Li4.   

Abstract

The effect of hydronephrosis, a common complication of metastatic colorectal cancer (CRC), on the treatment outcome and prognosis of locally advanced or metastatic CRC remains to be elucidated. The present study investigated the clinical characteristics, outcomes, and prognoses of patients with locally advanced or metastatic colorectal cancer (CRC) with hydronephrosis. Clinical data of patients with locally advanced or metastatic CRC who were attending Peking University Shenzhen Hospital and Shenzhen Cancer Hospital between January 2016 and December 2020 were retrospectively collected. A total of 52 patients with hydronephrosis based on CT or MRI findings were selected, and their clinical characteristics, treatment outcomes, and survival times were analyzed. Of the 52 patients, 33 were male (63.5%), and the median age was 49 years (range, 31-76 years). A total of 15 (28.8%) patients with CRC had synchronous hydronephrosis and the remaining 37 patients had metachronous hydronephrosis. Ureters were either compressed by peritoneal or abdominal cavity metastatic lymph nodes in 34 cases (65.4%) or by direct tumor invasion in 18 cases (34.6%). However, objective response rate (ORR) was higher in the group in which ureters were compressed by peritoneal or abdominal cavity metastatic lymph nodes; ORR, disease control rate and median progression-free survival (PFS) between the two groups were not statistically different. (P>0.05). The median survival period was only 27.0 months (95% CI, 20.549-33.451) in patients complicated with malignant hydronephrosis. Univariate and multivariate analyses showed that CA19-9 might be a prognostic factor for locally advanced and metastatic CRC patients with hydronephrosis. Metachronous metastatic CRC has a high incidence rate of complicated hydronephrosis. Targeted drugs in combination with chemotherapy improve the treatment efficacy and prognosis of patients. Notably, the present study found that CA19-9 level might be a prognostic factor in CRC patients with hydronephrosis.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  CA19-9; colorectal cancer; hydronephrosis; outcome; prognosis

Year:  2022        PMID: 35620214      PMCID: PMC9112401          DOI: 10.3892/mco.2022.2539

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  22 in total

1.  Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer.

Authors:  Qing Zhang; Jeremy Tey; Zhe Yang; Ping Li; Lihua Peng; Shen Fu; Guofeng Huang; Fei Xiong; Jiade J Lu
Journal:  Am J Clin Oncol       Date:  2015-02       Impact factor: 2.339

2.  CT detection of hydronephrosis in resected colorectal cancer: a predictor of recurrent disease.

Authors:  G Brown; A E Drury; D Cunningham; J E S Husband
Journal:  Clin Radiol       Date:  2003-02       Impact factor: 2.350

3.  [A Case of Laparoscopic Hepatectomy and Combined Resection of Lymph Nodes and Ureter for Liver Metastasis after Colorectal Cancer Surgery, with Local Lymph Node Recurrence and Bilateral Hydronephrosis].

Authors:  Toshihiro Sato; Hisamune Sakai; Yuuichi Goto; Satoki Kojima; Yoriko Nomura; Goichi Nakayama; Yuusuke Hirakawa; Kazuhiro Mikagi; Ryuuichi Kawahara; Hiroto Ishikawa; Toru Hisaka; Masafumi Yasunaga; Hiroyuki Tanaka; Yoshito Akagi; Kouji Okuda
Journal:  Gan To Kagaku Ryoho       Date:  2019-04

4.  [Two Cases of CT-Guided Radiofrequency Ablation Therapy for Pelvic Recurrence from Rectal Cancer].

Authors:  Michiko Hamanaka; Masafumi Noda; Ayako Imada; Jihyung Song; Kei Kimura; Akihito Babaya; Masayoshi Kobayashi; Kiyoshi Tsukamoto; Haruyuki Takaki; Tomoki Yamano; Masataka Ikeda; Koichiro Yamakado; Naohiro Tomita
Journal:  Gan To Kagaku Ryoho       Date:  2018-12

5.  Is there a role for curative surgery for pelvic recurrence from rectal carcinoma in the presence of hydronephrosis?

Authors:  C Cheng; M A Rodriguez-Bigas; N Petrelli
Journal:  Am J Surg       Date:  2001-09       Impact factor: 2.565

Review 6.  Urinary tract involvement by colorectal cancer.

Authors:  Deborah A McNamara; John M Fitzpatrick; P Ronan O'Connell
Journal:  Dis Colon Rectum       Date:  2003-09       Impact factor: 4.585

7.  [A case of locally advanced sigmoid colon cancer treated with neoadjuvant chemoradiotherapy].

Authors:  Mami Yoshitomi; Hiroki Hashida; Akinari Nomura; Shugo Ueda; Hiroaki Terajima; Nobuhiro Osaki
Journal:  Gan To Kagaku Ryoho       Date:  2014-09

8.  Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.

Authors:  Gong Chen; Junjie Peng; Qian Xiao; Hao-Xiang Wu; Ke-Feng Ding; Sanjun Cai; Feng Wang; Rui-Hua Xu; Xiaojun Wu; Fulong Wang; Liren Li; Peirong Ding; Qi Zhao; Yaqi Li; Da Wang; Yang Shao; Hua Bao; Zhizhong Pan
Journal:  J Hematol Oncol       Date:  2021-05-17       Impact factor: 17.388

Review 9.  Effects of molecular markers on the treatment decision and prognosis of colorectal cancer: a narrative review.

Authors:  Yujuan Cao; Xiaodong Wang
Journal:  J Gastrointest Oncol       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.